Market closedADR

Mereo BioPharma Group/$MREO

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Mereo BioPharma Group

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

Ticker

$MREO
Trading on

Industry

Biotechnology

Employees

33

MREO Metrics

BasicAdvanced
$630M
Market cap
-
P/E ratio
-$0.26
EPS
0.97
Beta
-
Dividend rate
$630M
0.97
$5.02
$1.86
574K
6.074
5.784
0.702
7.835
-22.39%
-23.86%
-48.47%
573.667
8
8.09
-27.68
-88.89%
-2.67%
-72.11%
-18.95%

What the Analysts think about MREO

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Mereo BioPharma Group stock.

MREO Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

MREO Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $MREO

$

Sign up or log in to buy
Capital at risk
Market closedADR

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Mereo BioPharma Group stock?

Mereo BioPharma Group (MREO) has a market cap of $630M as of November 13, 2024.

What is the P/E ratio for Mereo BioPharma Group stock?

The price to earnings (P/E) ratio for Mereo BioPharma Group (MREO) stock is 0 as of November 13, 2024.

Does Mereo BioPharma Group stock pay dividends?

No, Mereo BioPharma Group (MREO) stock does not pay dividends to its shareholders as of November 13, 2024.

When is the next Mereo BioPharma Group dividend payment date?

Mereo BioPharma Group (MREO) stock does not pay dividends to its shareholders.

What is the beta indicator for Mereo BioPharma Group?

Mereo BioPharma Group (MREO) has a beta rating of 0.97. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.